MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.730
-0.130
-4.55%
After Hours: 2.920 +0.19 +6.96% 17:48 01/24 EST
OPEN
2.918
PREV CLOSE
2.860
HIGH
2.918
LOW
2.700
VOLUME
25.18K
TURNOVER
--
52 WEEK HIGH
24.45
52 WEEK LOW
2.700
MARKET CAP
10.25M
P/E (TTM)
-0.6434
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SLRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SLRX News

  • The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
  • Benzinga.01/14 12:55
  • ACST, ADAP, SSI and VBIV among midday movers
  • Seeking Alpha - Article.01/13 17:39
  • Salarius Pharma files for equity offering
  • seekingalpha.01/11 02:46
  • Salarius Pharmaceuticals to Present at Biotech Showcase 2020
  • GlobeNewswire.12/19/2019 13:00

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About SLRX

Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.
More

Webull offers Salarius Pharmaceuticals Inc (SLRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.